Patents Issued in March 8, 2016
-
Patent number: 9278082Abstract: The present invention is directed to a method for treating skin inflammatory diseases such as dermatitis, psoriasis, and acne, and rosacea, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. The method alleviates the symptoms of the disease treated. The active compound can be administered by a systemic route or topical route. Topical administration is a preferred route of administration.Type: GrantFiled: July 10, 2015Date of Patent: March 8, 2016Assignee: OLATEC INDUSTRIES LLCInventor: Joseph P. St. Laurent
-
Patent number: 9278083Abstract: Methods for making trans-(?)-?9-tetrahydrocannabinoI and trans-(+)-?9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(?)-?9-tetrahydrocannabinoI composition is prepared by allowing a composition comprising (±)-?9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(?)-?9-tetrahydrocannabinoI composition comprising at least about 99% by weight of trans-(?)-?9-tetrahydrocannabinol based on the total amount of trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(?)-?9-tetrahydrocannabinoI having a purity of at least about 98% based on the total weight of cannabinoids.Type: GrantFiled: January 13, 2015Date of Patent: March 8, 2016Assignee: SVC Pharma LPInventors: Arie L. Gutman, Marina Etinger, Irina Fedotev, Ram Khanolkar, Gennady A. Nisnevich, Boris Pertsikov, Igor Rukhman, Boris Tishin
-
Patent number: 9278084Abstract: The present invention relates to combinations of an agent that stimulates cell proliferation and an anti-inflammatory/analgesic, which are useful in the treatment of peripheral ulcers of various origins, such as radiation dermatitis, diabetic ulcers, ulcers caused by venous stasis of the limbs, bedsores, and the associated skin infections, proctitis, vulvovaginitis and haemorrhoids with vascular lesions. These combinations can be presented as formulations for topical use.Type: GrantFiled: September 13, 2012Date of Patent: March 8, 2016Assignee: INDENA S.P.A.Inventor: Ezio Bombardelli
-
Patent number: 9278085Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.Type: GrantFiled: February 22, 2007Date of Patent: March 8, 2016Assignee: Edison Pharmaceuticals, Inc.Inventors: Guy M. Miller, Sidney M. Hecht, Orion D. Jankowski, Kieron E. Wesson, Paul Mollard
-
Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
Patent number: 9278086Abstract: The invention relates to compounds, methods, uses, compositions, combinations, kits and packages for the prevention and/or treatment of parasite infection (e.g., Plasmodium parasites) and/or disease (e.g., malaria) based on uses of (a) cystamine, cysteamine, and analogs, derivatives, prodrugs, precursors thereof; an agent capable of inducing their production; and/or salts thereof, and (b) artemisinin and functional derivative, analog, conjugate, metabolite, prodrug or precursor thereof, and/or salts thereof.Type: GrantFiled: July 16, 2014Date of Patent: March 8, 2016Assignee: The Royal Institution for the Advancement of Learning/McGill UniversityInventors: Philippe Gros, Gundula Min-Oo, Anny Fortin -
Patent number: 9278087Abstract: (?)-(S)-3-(3?-hydroxy)-butylphthalide (a compound shown by Formula I) and an ester formed of the same and an acid are proved by experiments to be applicable to treatment and prevention of cerebral ischemic diseases and have a sleep-improving function. The acid refers to a pharmaceutically acceptable inorganic or organic acid. The inorganic acid refers to nitric acid, sulfuric acid, or phosphoric acid. In addition to an acid radical, the organic acid at least comprises at least one of an amino group, a hydroxyl group, and a carboxyl group. None of the compound shown by Formula I and the ester thereof is water-soluble. An ester generated from the compound and the acid further react with an acid or a base to generate a salt which is water-soluble and is used to prepare injection preparation. The experiment proves that the salt does not stimulate vessels.Type: GrantFiled: September 26, 2012Date of Patent: March 8, 2016Assignee: Shijiazhuang Yiling Pharmaceutical Co., Ltd.Inventors: Wei Wang, Yayao Zhou, Ya'nan Liu
-
Patent number: 9278088Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.Type: GrantFiled: April 11, 2013Date of Patent: March 8, 2016Assignee: Xenon Pharmaceuticals Inc.Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
-
Patent number: 9278089Abstract: A method of treating an Hepatitis C Virus infection in a patient, comprising providing a therapeutically effective amount, to a patient in need thereof, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: G1 is a group of the formula or where n is 0, 1, 2, 3, or 4 and Het is a 5- or 6-membered heteroaryl group containing 1 to 4 heteroatoms independently chosen from N, O, and S, which Het is optionally substituted.Type: GrantFiled: October 26, 2012Date of Patent: March 8, 2016Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: David Waugh, Christopher Self, Guangtao Zhang, Yves Pommier, Robert H. Shoemaker, Michael Currens, John Cardellina, Andrew Jobson, George Lountos, Dominic Scudiero
-
Patent number: 9278090Abstract: Disclosed is a method of preventing the development of mucositis in a subject undergoing radiation therapy or chemotherapy for a disease in need thereof comprising administering an effective amount of a mammalian target of rapamycin (mTOR) inhibitor, such as rapamycin, to the subject. Further disclosed is a method of increasing the lifespan of a normal oral keratinocyte and/or reducing oxidative stress in a normal epithelial cell, wherein the method comprises administering an effective amount of an mTOR inhibitor to a subject undergoing radiation therapy or chemotherapy for a disease in need thereof.Type: GrantFiled: March 13, 2013Date of Patent: March 8, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: J. Silvio Gutkind, Ramiro Iglesias-Bartolome, Vyomesh Patel, Ana p. Cotrim, Alfredo Molinolo, James B. Mitchell
-
Patent number: 9278091Abstract: Disclosed are compounds of formula (I): and pharmaceutically acceptable N-oxides, salts, hydrates, solvates, complexes, bioisosteres, metabolites, and prodrugs thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.Type: GrantFiled: February 12, 2015Date of Patent: March 8, 2016Assignee: Summit Therapeutics PLCInventors: Peter David Johnson, Richard John Vickers, Francis Xavier Wilson, Colin Richard Dorgan, Lauren Jayne Sudlow, Stephen Paul Wren, Renate Maria van Well
-
Patent number: 9278092Abstract: There is described a method for increasing the maximal tolerated close and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetyl choline esterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HT3 receptor antagonist, a dopamine antagonist, a H1-receptor antagonist, a cannabinoid agonist, aprepitant or casopitant as an antiemetic agent and (b) an acetylcholine esterase inhibitor are also described.Type: GrantFiled: September 18, 2014Date of Patent: March 8, 2016Assignee: Chase Pharmaceuticals CorporationInventors: Thomas N. Chase, Kathleen E. Clarence-Smith
-
Patent number: 9278093Abstract: This invention relates to tricyclic triazole compounds or their pharmaceutically acceptable salts. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the above-cited compounds or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.Type: GrantFiled: March 29, 2013Date of Patent: March 8, 2016Assignees: Merck Sharp & Dohme Corp., ElexoPharm GmbHInventors: Amjad Ali, Emmanuel Bey, Rolf Hartmann, Quingzhong Hu, Lina Yin
-
Patent number: 9278094Abstract: The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists.Type: GrantFiled: March 5, 2015Date of Patent: March 8, 2016Assignee: PHARMORX THERAPEUTICS, INC.Inventors: David M. Bear, Robert M. Kessler
-
Patent number: 9278095Abstract: This disclosure relates to methods administering bupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion or a prodrug of bupropion are also disclosed.Type: GrantFiled: September 23, 2015Date of Patent: March 8, 2016Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9278096Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.Type: GrantFiled: November 12, 2008Date of Patent: March 8, 2016Assignees: H. Lundbeck A/S, Takeda Pharmaceuticals North America, Inc.Inventor: Marianne Dragheim
-
Patent number: 9278097Abstract: The invention provides a medication for the prophylaxis and/or therapy against diseases or complications in connection with portal hypertension, particularly against bleeding complications.Type: GrantFiled: June 3, 2004Date of Patent: March 8, 2016Assignee: Universitatsklinikum FreiburgInventors: Wolfgang Kreisel, Peter Deibert
-
Patent number: 9278098Abstract: Phthalazine analogs of a Lisofylline (LSF) and synthetic methods for preparation of such analogs are provided. Compounds of the invention have structural formula III: wherein 1) R3a is hydrogen and R3b is selected from C5-22alkyl, C2-22alkenyl, or C2-22alkynyl; or a pharmaceutically acceptable salt thereof; or 2) R3b is hydrogen and R3a is selected from C9alkyl, C15-22alkyl, C9-22alkenyl, or C2-22alkynyl; or a pharmaceutically acceptable salt thereof; or 3) R3a and R3b are the same or different and are selected from C9alkyl, C15-22alkyl, C4-22alkenyl, or C2-22alkynyl; or a pharmaceutically acceptable salt thereof. The analogs of LSF provided have the ability to protect cell viability, particularly the ability to protect pancreatic ?-cells, to induce insulin secretion.Type: GrantFiled: October 27, 2014Date of Patent: March 8, 2016Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Timothy L. MacDonald, Jerry L. Nadler, Peng Cui
-
Patent number: 9278099Abstract: A granulation formulation of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide or pharmaceutically acceptable salt thereof, which is adapted for reconstitution with an aqueous vehicle, and associated oral suspension.Type: GrantFiled: October 16, 2012Date of Patent: March 8, 2016Assignee: Novartis AGInventors: Gossett Augustus Campbell, Helen Richardson, Peter A. Williams
-
Patent number: 9278100Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.Type: GrantFiled: December 30, 2011Date of Patent: March 8, 2016Assignee: Pharmacyclics LLCInventors: Lee Honigberg, Erik Verner, Joseph Buggy, David Loury, Wei Chen
-
Patent number: 9278101Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.Type: GrantFiled: February 21, 2014Date of Patent: March 8, 2016Assignee: Omeros CorporationInventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
-
Patent number: 9278102Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: July 21, 2014Date of Patent: March 8, 2016Assignee: Ardelyx, Inc.Inventors: Jason G. Lewis, Jeffrey W. Jacobs, Nicholas Reich, Michael R. Leadbetter, Noah Bell, Han-Ting Chang, Tao Chen, Marc Navre, Dominique Charmot, Christopher Carreras, Eric Labonte
-
Patent number: 9278103Abstract: Substituted 6-amino-nicotinamides, pharmaceutical compositions containing these compounds and also use of these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders.Type: GrantFiled: March 31, 2014Date of Patent: March 8, 2016Assignee: GRÜNENTHAL GMBHInventors: Sven Kühnert, Gregor Bahrenberg, Achim Kless, Wolfgang Schröder, Simon Lucas
-
Patent number: 9278104Abstract: A composition containing nelumbo extract reduces and/or eliminates one or more risk factors associated with Metabolic syndrome. The composition also includes optionally one of more components selected from the group consisting of vitamins, cholesterol lowering agents, lipid lowering agents, and glucose lowering agent. Also described is a method of reducing and/or eliminating risk factors associated with Metabolic syndrome in a subject through the administration of the nelumbo extract. The nelumbo extract supplement is administered orally, intravenously, or subcutaneously. In one embodiment, a daily dose of 10-1,000 mg of the extract supplement is administered to the subject for a period of 6 weeks to 6 months.Type: GrantFiled: October 26, 2011Date of Patent: March 8, 2016Assignee: IN Ingredients, Inc.Inventor: Tim Romero
-
Patent number: 9278105Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.Type: GrantFiled: October 17, 2012Date of Patent: March 8, 2016Assignee: Rempex Pharmaceuticals, Inc.Inventors: David C. Griffith, Serge Boyer, Michael N. Dudley, Scott Hecker
-
Patent number: 9278106Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabilty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.Type: GrantFiled: May 15, 2014Date of Patent: March 8, 2016Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9278107Abstract: Disclosed is an antibacterial agent composition which is highly safe and has excellent antibacterial abilities, by using a silicon-containing compound that is obtained by a specific manufacturing method. The antibacterial agent composition has a more stable antibacterial component, and is capable of imparting antibacterial abilities to teeth, while being also capable of cleaning an article or the mouth. Also disclosed are: an antiviral agent composition which is highly safe and has excellent virus deactivation abilities; an antibacterializing method, a cleaning/mouth rinsing method, each using the antibacterial agent composition or the antiviral agent composition; and a method for fixing an antibacterial agent or an antiviral agent. The antibacterial agent composition may contain a silicon-containing compound which is represented by general formula (1) and obtained by reacting a specific triethoxysilyl compound in an ethanol solvent.Type: GrantFiled: November 5, 2009Date of Patent: March 8, 2016Assignee: Hiroshima UniversityInventors: Hiroki Nikawa, Hironori Takeda, Toshio Kakihara, Takemasa Sakaguchi
-
Patent number: 9278108Abstract: A nucleic acid molecule that can bind to HMGB1 protein and applications thereof are provided. A nucleic acid molecule having a dissociation constant for HMGB1 protein of 5×10?7 or less can be used as the nucleic acid molecule that can bind to HMGB1 protein. The HMGB1 binding nucleic acid molecule can bind to HMGB1 protein that is known to be a cause of diseases such as cancer and inflammation, and it is therefore possible to obtain an effect to prevent and an effect to treat such diseases by allowing the HMGB1 binding nucleic acid molecule to bind to HMGB1 protein in a living body.Type: GrantFiled: July 16, 2010Date of Patent: March 8, 2016Assignees: NEC Solution Innovators, Ltd., Kanagawa Prefectural Hospital OrganizationInventors: Hiromi Takenaka, Jou Akitomi, Shintarou Katou, Shotaro Tsuji, Takashi Ohtsu, Iwao Waga
-
Patent number: 9278109Abstract: The present invention relates to compositions comprising vitamins, minerals and other nutrients and methods for using these compositions for nutritional supplementation to prevent and/or alleviate a patient from the occurrence or negative effects of cardiovascular disease. Specifically, the invention relates to compositions and methods of administering compositions comprising natural CoQ10, natural Omega-3 fatty acids, natural bioflavonoids, natural vitamin E, amino acids and derivatives thereof, minerals, extra virgin olive oil, lecithin, B-complex vitamins, and antioxidants.Type: GrantFiled: September 4, 2013Date of Patent: March 8, 2016Inventors: Michael J Gonzalez, Angel E Gil, Jesus G Gil
-
Patent number: 9278110Abstract: The invention relates to compositions intended for reducing, ideally for eliminating, regurgitation and/or gastro-oesophageal reflux phenomena affecting a subject. Anti-regurgitation and/or anti-reflux infant formulas and milks intended for feeding newborn babies, infants and young children are more particularly described.Type: GrantFiled: March 30, 2015Date of Patent: March 8, 2016Assignee: UNITED PHARMACEUTICALSInventors: Jonathan Albert Margossian, Nicolas Pradeau, Yannick Fallourd
-
Patent number: 9278111Abstract: A method and system for generating and delivering nitric oxide directly to a patient. A reaction chamber is provided that is located at or in close proximity to the patient and reactants within the reaction chamber react together to produce a predetermined amount of nitric oxide. The reaction is controlled by metering at least one of the reactants into the reaction chamber to generate a predetermined quantity of nitric oxide as required by the patient. The reactants can include a nitrite salt, such as sodium nitrite, and a reductant such as ascorbic acid, maleic acid or a mixture thereof. By generating and delivering the nitric oxide directly to the patient in close proximity thereto, the formation of NO2 is minimized. One or both of the reactants may be in liquid form.Type: GrantFiled: June 18, 2014Date of Patent: March 8, 2016Assignee: INO Therapeutics LLCInventors: Frederick J. Montgomery, Duncan P. Bathe
-
Patent number: 9278112Abstract: Provided are beverage compositions comprising a urine citrate increasing component and a urine oxalate reducing component. The beverage compositions may be provided in a ready-to-drink form or may be provided in a concentrate form. Also provided are kits comprising the beverage compositions and methods for treating various conditions using the beverage compositions.Type: GrantFiled: March 14, 2014Date of Patent: March 8, 2016Assignees: New York University, General Hospital Corporation, The Regents of the University of CaliforniaInventors: David S. Goldfarb, Brian Eisner, John Asplin, Marshall L. Stoller
-
Patent number: 9278113Abstract: The present disclosure describes compositions operable for releasing nitric oxide under photochemical conditions. The compositions include a titanium dioxide nanomaterial and a nitric oxide-releasing compound deposited on the titanium dioxide nanomaterial that is operable to release nitric oxide under photochemical conditions. Titanium dioxide nanomaterials include, for example, titanium dioxide nanotubes. To facilitate the photochemical release of nitric oxide, some embodiments of the compositions further include a semiconductor that is deposited on the titanium dioxide nanotubes. Both the semiconductor and the nitric oxide-releasing compound may be deposited on the interior surface, exterior surface, or both of the titanium dioxide nanotubes. A polymer may wrap the titanium dioxide nanotubes to protect the nitric oxide-releasing compounds from moisture. Also disclosed herein are methods for producing such compositions and medical devices obtained therefrom.Type: GrantFiled: March 30, 2010Date of Patent: March 8, 2016Assignee: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Kenneth J. Balkus, Jr., Chalita Ratanatawanate
-
Patent number: 9278114Abstract: A material for treatment of cerebral infarction ameliorates angiopathy at a cerebral infarction region and improves brain function. The material for treatment of cerebral infarction according to the present invention comprises a dental pulp stem cell including at least one of a CD105-positive cell, an SP cell, a CD24-positive cell, a CD271-positive cell, and a CD150-positive cell. The material for treatment of cerebral infarction according to the present invention may contain a secretory protein of the dental pulp stem cell. Transplanted dental pulp stem cells do not directly differentiate into neural progenitor cells or neural cells and indirectly participate in the promotion of differentiation to restore and cure a cerebral infarction region such that the region becomes normal.Type: GrantFiled: August 20, 2013Date of Patent: March 8, 2016Assignee: National Center for Geriatrics and GerontologyInventors: Misako Nakashima, Masahiko Sugiyama
-
Patent number: 9278115Abstract: A bacterial composition that inhibits E. coli O157:H7 growth by as much as 93% and Salmonella growth by as much as 97%, together with commensurate inhibition rates against the Big-Six Escherichia coli strains referred to as the non-O157 STECs that include E. coli O121:H19; E. coli O45:H2; E. coli O103:H11; E. coli O145, E. coli O26:H11; and E. coli O111. The composition is constituted of various combinations of the following four unique pathogen-inhibiting bacteria: (1) Lactobacillus animalis strain MB101; (2) Lactobacillus animalis strain MB102; (3) Enterococcus faecium strain MB505; and (4) Pediococcus acidilactici strain MB902. Each of the discovered bacteria is deposited with the American Type Culture Collection (ATCC) and respectively has an individual ATCC Accession Number.Type: GrantFiled: December 31, 2014Date of Patent: March 8, 2016Assignee: MICROBIOS, INC.Inventors: Joseph F. Flint, Matthew Ryan Garner
-
Patent number: 9278116Abstract: The present invention relates to a homeopathic formulation comprising dilutions of Arnica, Calendula, Echinacea, Hypericum, Silver, Sulfur, Thiosinaminum, Urtica, and methods for treating pain, inflammation, scar tissue, itching/pruritus and infection using same.Type: GrantFiled: March 12, 2013Date of Patent: March 8, 2016Assignee: Princeton Biotechnology CorporationInventor: Frank Demuro
-
Patent number: 9278117Abstract: Provided are a composition and method for the safe and effective inhibition of pancreatic lipase in humans and other mammals. Provided is a composition which contains extracts of one or more of Coleus forskohlii, Salacia reticulata, and Sesamum indicum, and which is administered orally to humans and other mammals in a nutritionally or pharmacologically effective amount. Further provided is a method for producing said composition.Type: GrantFiled: April 1, 2013Date of Patent: March 8, 2016Assignee: Bio Actives Japan CorporationInventors: Mohamed Faizal, Hiroshi Nishida, Vladimir Badmaev
-
Patent number: 9278118Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.Type: GrantFiled: October 20, 2014Date of Patent: March 8, 2016Assignees: BIOREC S.A., CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Silvio Ernesto Perea Rodriguez, Yasser Perera Negrin, Arielis Rodríguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lázaro Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
-
Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients
Patent number: 9278119Abstract: The present invention relates to a Wnt5a protein or peptide thereof possessing Wnt5a signaling properties, such as Foxy5, for use in the treatment of prostate cancer, in particular in patients that have undergone or will undergo radical prosteatectomy. The invention also relates to a method for determining a prognosis for a patient having prostate cancer and a kit for performing said method. The method for determining a prognosis for a patient comprises the steps of: evaluating an amount of Wnt5a protein present in at least part of a sample earlier obtained from the patient and determining a sample value corresponding to the evaluated amount; comparing the sample value obtained in step a) with a reference value associated with a reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said patient is better than said reference prognosis.Type: GrantFiled: June 28, 2012Date of Patent: March 8, 2016Assignee: WNTRESEARCH ABInventors: Tommy Andersson, Anders Bjartell -
Patent number: 9278120Abstract: Provided herein are methods of evaluating efficacy of a treatment in a subject having eye inflammation (e.g., a subject having dry eye syndrome) and selecting a subject for participation in a clinical study. Also provided are methods of treating a subject having eye inflammation (e.g., a subject having dry eye syndrome).Type: GrantFiled: August 20, 2013Date of Patent: March 8, 2016Assignee: Massachusetts Eye and Ear InfirmaryInventors: Andrea Cruzat, Pedram Hamrah, Reza Dana, Bernardo Cavalcanti
-
Patent number: 9278121Abstract: The present invention encompasses methods for treating an infection and/or treating or reducing inflammation through the administration of a therapeutically effective amount of a peptide to a subject in need thereof. In some aspects, the peptide is a Helicobacter pylori-derived peptide, such as an HPA3NT3 peptide and the infection is a bacterial infection.Type: GrantFiled: March 14, 2013Date of Patent: March 8, 2016Assignees: The Board of Trustees of the University of Arkansas, Chosun UniversityInventors: Peter I. Song, Cheryl Armstrong, Sunhyo Ryu, Yoonkyung Park, Kyung-soo Hahm
-
Patent number: 9278122Abstract: The present invention provides methods and compositions designed for treating a subject suffering from skin conditions, disorders or diseases. The compositions include fetal skin cell proteins obtained from fetal skin cells after induced cell lysis.Type: GrantFiled: May 13, 2013Date of Patent: March 8, 2016Assignee: MERZ GMBH & CO. KGAAInventors: Lee Laurent-Applegate, Patrick Hohlfeld
-
Patent number: 9278123Abstract: The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.Type: GrantFiled: December 16, 2011Date of Patent: March 8, 2016Assignee: Novo Nordisk A/SInventors: Per Sauerberg, Simon Bjerregaard, Flemming Seier Nielsen
-
Patent number: 9278124Abstract: Provided herein are diagnostic methods for identifying subjects susceptible to treatment with a hypoxia-activated agent, and related methods. Also provided herein are methods of monitoring treatments with anti-hyaluronan agents, and related methods.Type: GrantFiled: October 16, 2013Date of Patent: March 8, 2016Assignee: Halozyme, Inc.Inventors: H. Michael Shepard, Xiaoming Li, Curtis Thompson
-
Patent number: 9278125Abstract: Disclosed herein are pharmaceutical compositions comprising Plasmodium sporozoite-stage parasites and compatible glycolipid adjuvants useful in vaccines for preventing or reducing the risk of malaria. In particular, human host range Plasmodium and analogues of ?-galactosylceramide (?-GalCer), a ligand for natural killer T (NKT) cells, are combined in pharmaceutical compositions, which are useful as vaccines against malaria. Methods of use are also provided.Type: GrantFiled: October 28, 2013Date of Patent: March 8, 2016Assignees: SANARIA INC., THE ROCKEFELLER UNIVERSITYInventors: Sumana Chakravarty, Stephen L. Hoffman, Moriya Tsuji
-
Patent number: 9278126Abstract: Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 ?g/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.Type: GrantFiled: February 10, 2010Date of Patent: March 8, 2016Assignee: Seqirus UK LimitedInventors: Mario Contorni, Derek O'hagan, Nicola Groth
-
Patent number: 9278127Abstract: The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunizing against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolizable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.Type: GrantFiled: June 17, 2011Date of Patent: March 8, 2016Assignee: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Emmanuel Jules Hanon, Jean Stephenne
-
Patent number: 9278128Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-15Ra or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.Type: GrantFiled: January 6, 2014Date of Patent: March 8, 2016Assignee: The Trustees of the University of PennsylvaniaInventors: David B. Weiner, Kimberly A. Kraynyak, Michele Kutzler
-
Patent number: 9278129Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g.Type: GrantFiled: February 12, 2015Date of Patent: March 8, 2016Assignee: Immunomedics, Inc.Inventors: Chien-Hsing Chang, Hans J. Hansen, David M. Goldenberg
-
Patent number: 9278130Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.Type: GrantFiled: February 12, 2014Date of Patent: March 8, 2016Assignee: AXOLABS GMBHInventors: Rainer Constien, Anke Geick, Philipp Hadwiger, Torsten Haneke, Ludger Markus Ickenstein, Carla Alexandra Hernandez Prata, Andrea Schuster, Timo Weide
-
Patent number: 9278131Abstract: A process of lowering the viscosity of a solution includes preparing a solution comprising a compound of formula I, at a concentration in the final formulation of between 10 and 250 mM, and a protein having at least one antibody fragment whose concentration is between 50 and 350 mg/mL and whose pH is between 5 and 8. The compound lowers the viscosity of the solution, which is difficult to inject, by a value of at least 15% relative to the viscosity of a solution of at least one protein having at least one antibody fragment of the same concentration and of the same pH not containing the compound.Type: GrantFiled: August 8, 2013Date of Patent: March 8, 2016Assignee: ADOCIAInventors: Emmanuel Dauty, Thomas Ballet, Remi Soula